SK Life Science Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd. – an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders – will present data from a pooled analysis from studies C013/C017 OLEs and C021 evaluating the cognitive and psychiatric treatment-related adverse events during adjunctive treatment with anti-seizure medication XCOPRI® (cenobamate tablets) CV at the American Academy of Neurology Annual Meeting, held in-person in Seattle April 2–7, 2022.

New York-based Ovid Therapeutics and Healx entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).

Eight years ago, a group of scientists began to carefully repeat early laboratory experiments in cancer research that had much influence on the field. In their study, they recreated 50 experiments and found that 54% of the studies could not be reproduced. The results were published in eLife, a nonprofit that receives funding from the Howard Hughes Medical Institute.

A study by The National Institutes for Quantum Science and Technology in Japan found that a supplement with seven specific amino acids called Amino LP7 appeared to slow brain degeneration and dementia development in mice.

The U.S. Food and Drug Administration awarded Roche’s Alzheimer’s disease drug candidate Breakthrough Therapy Designation, bringing the IgG1 antibody gantenerumab closer to finally receiving full FDA approval. 

A group of scientists from the Nuffield Department of Women’s & Reproductive Health at Oxford University may have found a potential key to finally treating endometriosis, a disease that affects around 176 million women worldwide. 

A study in Science shed new light on the global epidemic obesity by evaluating nearly 650,000 exomes from the United Kingdom, United States and Mexico and identifying those with strong implications for body mass or obesity.

A study found potential in a novel gene therapy method to help children born with a rare genetic and neurodegenerative disorder, AADC deficiency.

The successful use of messenger RNA (mRNA) vaccines for Covid-19 has led to a flurry of research studies designed to test these candidates in other illnesses. Translate Bio, for instance, launched a Phase I clinical trial with Sanofi’s vaccines global business unit Sanofi Pasteur to evaluate an mRNA-based investigational vaccine for the flu.

Gilead Sciences Inc. said an analysis showed the company’s antiviral remdesivir reduced mortality rates in hospitalized patients with Covid-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment.